Little Green Pharma Finalises Merger with Cannatrek to Form Leading Medicinal Cannabis Group
Little Green Pharma (ASX:LGP) has completed its merger with Cannatrek, creating a dominant player in Australia and Europe’s medicinal cannabis market with a majority stake held by former Cannatrek shareholders.
- Merger approved by shareholders and Federal Court
- Cannatrek shareholders hold 60.5% of combined entity
- Integrated operations across cultivation, manufacturing, clinics, and digital health
- Leadership reshuffle with new board appointments and retirements
- Revised CEO remuneration linked to merger implementation
Merger Completion Establishes Major Medicinal Cannabis Player
Little Green Pharma (ASX:LGP) has officially sealed its acquisition of Cannatrek Ltd, consolidating two of Australia’s most established medicinal cannabis businesses into a single powerhouse. The scheme of arrangement, approved by Cannatrek shareholders on 10 April and sanctioned by the Federal Court on 25 May, was implemented on 1 June, with all Cannatrek shares now transferred to LGP.
The merger dramatically reshapes the ownership structure: Cannatrek shareholders now hold approximately 60.5% of the fully diluted LGP, leaving existing LGP investors with around 39.5%. This significant shift highlights Cannatrek’s scale and contribution to the combined entity.
Integrated Operations Span Australia and Europe
The newly formed LGP Cannatrek Group boasts a vertically integrated platform covering cultivation, AU-GMP and EU-GMP certified manufacturing, distribution, clinics, and digital health platforms. Cannatrek’s robust Australian operations include one of the country’s largest medicinal cannabis manufacturing and storage facilities, a diversified product portfolio, and proprietary digital assets.
This merger aligns with broader industry trends emphasising scale and operational capability as critical to competing in both domestic and international medicinal cannabis markets. The combined group is positioned to capitalise on consolidation and expansion opportunities across Europe and other regulated markets.
Leadership Changes Signal Strategic Renewal
The merger brings notable changes to LGP’s board and executive team. Brent Dennison steps in as Independent Non-Executive Chair, while Paul Long continues as Group CEO. New directors Thomas Huppert and Seth Yakatan join the board, complementing existing independent director Michael Lynch Bell.
Meanwhile, the company bids farewell to long-serving directors Dr Neale Fong, founder Fleta Solomon, and Angus Caithness. Each played pivotal roles in LGP’s growth and international expansion, with Solomon recognised as a pioneer in Australia’s medicinal cannabis sector.
CEO Remuneration Adjusted for Merger Milestone
In conjunction with the merger, the board approved revised remuneration for Paul Long, increasing his fixed annual salary to $500,000 excluding superannuation and awarding a change of control bonus equal to 60% of base salary payable in six months. Long has also agreed to cancel all remaining performance rights held by him, signalling alignment with the group’s new phase.
The merger’s completion marks a critical inflection point for LGP, which has been expanding its European footprint amid strong revenue growth. The combined entity’s enhanced balance sheet and operational scale are expected to support accelerated growth and strategic initiatives.
Bottom Line?
The LGP Cannatrek merger creates a formidable medicinal cannabis group, but integration execution and international market dynamics will be key to realising anticipated synergies.
Questions in the middle?
- How quickly can LGP integrate Cannatrek’s operations to unlock cost and revenue synergies?
- What regulatory hurdles might impact the group’s European expansion plans?
- How will the new leadership team navigate competitive pressures in the global medicinal cannabis sector?
